Postponed clinical trials affect ALK finances – central phase III trials have been delayed
![ALK CEO Carsten Hellmann | Photo: Gregers Tycho/Ritzau/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13188909.ece/ALTERNATES/schema-16_9/20190626-111620-2-1920x1079we%2520(1).jpg)
Monday afternoon, Danish allergy company ALK upgraded the guidance for its main figures relating to revenue and earnings ahead of today's presentation of the firm's quarterly report.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
ALK increases sales in Q2, but operating result decreases
For subscribers
ALK upgrades guidance following convincing sales and savings
For subscribers